The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 4-5, 2009, Pages 433-443

  Lundahl, Anna ^a   Hedeland, Mikael ^a,b   Bondesson, Ulf ^a,b   Knutson, Lars ^c   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NATIONAL VETERINARY INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biliary excretion; Finasteride; Finasteride oic acid (Carboxy finasteride); Herb drug interactions; Human volunteers; Hypericum perforatum

Indexed keywords

CARBOXYFINASTERIDE; DRUG METABOLITE; FINASTERIDE; HYDROXYFINASTERIDE; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; MOVINA; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILE; BILE FLOW; BILIARY EXCRETION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ADMINISTRATION ROUTE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; GEOMETRY; HERB DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; INTRAINTESTINAL DRUG ADMINISTRATION; JEJUNUM; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ULTRAVIOLET RADIATION; URINARY EXCRETION;

ADULT; BICYCLO COMPOUNDS; BILIARY TRACT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FINASTERIDE; HALF-LIFE; HUMANS; HYPERICUM; MALE; PHLOROGLUCINOL; REFERENCE VALUES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY; TERPENES;

EID: 59349097187     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.11.009     Document Type: Article

References (48)

1. Agrosi M., Mischiatti S., Harrasser P.C., and Savio D. Oral bioavailability of active principles from herbal products in humans. A study on Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 7 (2000) 455-462
2. Andren L., Andreasson A., and Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur. J. Clin. Pharmacol. 63 (2007) 913-916
3. Bauer S., Stormer E., Graubaum H.J., and Roots I. Determination of hyperforin, hypericin, and pseudohypericin in human plasma using high-performance liquid chromatography analysis with fluorescence and ultraviolet detection. J. Chromatogr. B: Biomed. Sci. Appl. 765 (2001) 29-35
4. Bergman E., Forsell P., Tevell A., Persson E.M., Hedeland M., Bondesson U., Knutson L., and Lennernas H. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur. J. Pharm. Sci. 29 (2006) 205-214
5. Biber A., Fischer H., Romer A., and Chatterjee S.S. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31 Suppl 1 (1998) 36-43
6. Bonlokke L., Hovgaard L., Kristensen H.G., Knutson L., Lindahl A., and Lennernas H. A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. Eur. J. Pharm. Sci. 8 (1999) 19-27
7. Carlin J.R., Christofalo P., Arison B.H., Ellsworth R.E., Rosegay A., Miller R.R., Chiu S.H., and VandenHeuvel W.J. Disposition and metabolism of finasteride in dogs. Drug Metab. Dispos. 25 (1997) 100-109
8. Carlin J.R., Hoglund P., Eriksson L.O., Christofalo P., Gregoire S.L., Taylor A.M., and Andersson K.E. Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. Drug Metab. Dispos. 20 (1992) 148-155
9. Cui Y., Gurley B., Ang C.Y., and Leakey J. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 780 (2002) 129-135
10. Drake L., Hordinsky M., Fiedler V., Swinehart J., Unger W.P., Cotterill P.C., Thiboutot D.M., Lowe N., Jacobson C., Whiting D., Stieglitz S., Kraus S.J., Griffin E.I., Weiss D., Carrington P., Gencheff C., Cole G.W., Pariser D.M., Epstein E.S., Tanaka W., Dallob A., Vandormael K., Geissler L., and Waldstreicher J. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J. Am. Acad. Dermatol. 41 (1999) 550-554
11. Dresser G.K., Schwarz U.I., Wilkinson G.R., and Kim R.B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin. Pharmacol. Ther. 73 (2003) 41-50
12. Durr D., Stieger B., Kullak-Ublick G.A., Rentsch K.M., Steinert H.C., Meier P.J., and Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68 (2000) 598-604
13. Eggertsen R., Andreasson A., and Andren L. Effects of treatment with a commercially available St John's Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand. J. Prim. Health Care 25 (2007) 154-159
14. Faller B., Farley D., and Nick H. Finasteride: a slow-binding 5 alpha-reductase inhibitor. Biochemistry 32 (1993) 5705-5710
15. Godtel-Armbrust U., Metzger A., Kroll U., Kelber O., and Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Naunyn-Schmiedeberg's Arch. Pharmacol. 375 (2007) 377-382
16. Gormley G.J., Stoner E., Bruskewitz R.C., Imperato-McGinley J., Walsh P.C., McConnell J.D., Andriole G.L., Geller J., Bracken B.R., Tenover J.S., et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N. Engl. J. Med. 327 (1992) 1185-1191
17. Gormley G.J., Stoner E., Rittmaster R.S., Gregg H., Thompson D.L., Lasseter K.C., Vlasses P.H., and Stein E.A. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J. Clin. Endocrinol. Metab. 70 (1990) 1136-1141
18. Gunther S., Patterson R.E., Kristal A.R., Stratton K.L., and White E. Demographic and health-related correlates of herbal and specialty supplement use. J. Am. Diet. Assoc. 104 (2004) 27-34
19. Hu Z.P., Yang X.X., Chen X., Cao J., Chan E., Duan W., Huang M., Yu X.Q., Wen J.Y., and Zhou S.F. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr. Drug Metab. 8 (2007) 157-171
20. Huskey S.W., Dean D.C., Miller R.R., Rasmusson G.H., and Chiu S.H. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab. Dispos. 23 (1995) 1126-1135
21. Ishii Y., Mukoyama H., and Ohtawa M. In vitro biotransformation of finasteride in rat hepatic microsomes. Isolation and characterization of metabolites. Drug Metab. Dispos. 22 (1994) 79-84
22. Johne A., Brockmoller J., Bauer S., Maurer A., Langheinrich M., and Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin. Pharmacol. Ther. 66 (1999) 338-345
23. Kliewer S.A., Goodwin B., and Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 23 (2002) 687-702
24. Knutson L., Odlind B., and Hallgren R. A new technique for segmental jejunal perfusion in man. Am. J. Gastroenterol. 84 (1989) 1278-1284
25. Lennernas H., Ahrenstedt O., Hallgren R., Knutson L., Ryde M., and Paalzow L.K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9 (1992) 1243-1251
26. Lindahl A., Sandstrom R., Ungell A.L., Abrahamsson B., Knutson T.W., Knutson L., and Lennernas H. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin. Pharmacol. Ther. 60 (1996) 493-503
27. Lowe F.C., McConnell J.D., Hudson P.B., Romas N.A., Boake R., Lieber M., Elhilali M., Geller J., Imperto-McGinely J., Andriole G.L., Bruskewitz R.C., Walsh P.C., Bartsch G., Nacey J.N., Shah S., Pappas F., Ko A., Cook T., Stoner E., and Waldstreicher J. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 61 (2003) 791-796
28. Markowitz J.S., Donovan J.L., DeVane C.L., Taylor R.M., Ruan Y., Wang J.S., and Chavin K.D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290 (2003) 1500-1504
29. McConnell J.D., Bruskewitz R., Walsh P., Andriole G., Lieber M., Holtgrewe H.L., Albertsen P., Roehrborn C.G., Nickel J.C., Wang D.Z., Taylor A.M., and Waldstreicher J. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 338 (1998) 557-563
30. McConnell J.D., Wilson J.D., George F.W., Geller J., Pappas F., and Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 74 (1992) 505-508
31. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., and Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 7500-7502
32. Mueller S.C., Majcher-Peszynska J., Uehleke B., Klammt S., Mundkowski R.G., Miekisch W., Sievers H., Bauer S., Frank B., Kundt G., and Drewelow B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur. J. Clin. Pharmacol. 62 (2006) 29-36
33. Ohtawa M., Morikawa H., and Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. Eur. J. Drug Metab. Pharmacokinet. 16 (1991) 15-21
34. Oscarson M., Burk O., Winter S., Schwab M., Wolbold R., Dippon J., Eichelbaum M., and Meyer U.A. Effects of rifampicin on global gene expression in human small intestine. Pharmacogenet. Genom. 17 (2007) 907-918
35. Persson E.M., Nilsson R.G., Hansson G.I., Lofgren L.J., Liback F., Knutson L., Abrahamsson B., and Lennernas H. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm. Res. 23 (2006) 742-751
36. Piscitelli S.C., Burstein A.H., Chaitt D., Alfaro R.M., and Falloon J. Indinavir concentrations and St John's wort. The Lancet 355 (2000) 547-548
37. Rittmaster R.S., Stoner E., Thompson D.L., Nance D., and Lasseter K.C. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J. Androl. 10 (1989) 259-262
38. Ruschitzka F., Meier P.J., Turina M., Luscher T.F., and Noll G. Acute heart transplant rejection due to Saint John's wort. The Lancet 355 (2000) 548-549
39. Schulz H.U., Schurer M., Bassler D., and Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung 55 (2005) 15-22
40. Schwarz U.I., Hanso H., Oertel R., Miehlke S., Kuhlisch E., Glaeser H., Hitzl M., Dresser G.K., Kim R.B., and Kirch W. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin. Pharmacol. Ther. 81 (2007) 669-678
41. Steiner J.F. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin. Pharmacokinet. 30 (1996) 16-27
42. Sudduth S.L., and Koronkowski M.J. Finasteride: the first 5 alpha-reductase inhibitor. Pharmacotherapy 13 (1993) 309-329
43. Tannergren C., Engman H., Knutson L., Hedeland M., Bondesson U., and Lennernas H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin. Pharmacol. Ther. 75 (2004) 298-309
44. Vaughan D., Imperato-McGinley J., McConnell J., Matsumoto A.M., Bracken B., Roy J., Sullivan M., Pappas F., Cook T., Daurio C., Meehan A., Stoner E., and Waldstreicher J. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 60 (2002) 1040-1044
45. Vermeulen A., Giagulli V.A., De Schepper P., Buntinx A., and Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans. The Prostate 14 (1989) 45-53
46. Wang Z., Gorski J.C., Hamman M.A., Huang S.M., Lesko L.J., and Hall S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 70 (2001) 317-326
47. Whitten D.L., Myers S.P., Hawrelak J.A., and Wohlmuth H. The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br. J. Clin. Pharmacol. 62 (2006) 512-526
48. Winchell G.A., Gregoire S., Taylor A.M., Hegland J., and Hunninghake D.B. Finasteride, a steroid 5 alpha-reductase inhibitor, does not affect the oxidative metabolism of antipyrine. J. Clin. Pharmacol. 33 (1993) 967-970